Clinical Trial Update: A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial update on lenalidomide maintenance after first-line therapy in high-risk chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED